Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 3, 2012, Pages 251-263

  Espinoza, Stefano ^a   Managò, Francesca ^a   Leo, Damiana ^a   Sotnikova, Tatyana D ^a   Gainetdinov, Raul R ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

3 methoxytyramine; Dyskinesia; Entacapone; Nebicapone; TAAR1; Tolcapone; Trace amines

Indexed keywords

3',4' DIHYDROXY 2 METHYLPROPIOPHENONE; ASCORBIC ACID; BENSERAZIDE; BIA 3335; CAFFEIC ACID; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DIPYRONE; ENTACAPONE; GALLIC ACID; LEVODOPA; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; NEBICAPONE; NITECAPONE; OPICAPONE; PYROGALLOL; QUERCETIN; TOLCAPONE; TROPOLONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; CLINICAL GLOBAL IMPRESSION SCALE; CORPUS STRIATUM; DAILY LIFE ACTIVITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; ENZYME ACTIVITY; ENZYME INHIBITION; FIRST PASS EFFECT; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HUMAN; HYPOTHALAMUS; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROMODULATION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PREFRONTAL CORTEX; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; URINE; VOMITING;

EID: 84861760612     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800672436     Document Type: Review

References (169)

1. Schapira, A.H.; Jenner, P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord., 2011, 26, 1049-1055.
2. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
3. Dunnett, S.B.; Bjorklund, A. Prospects for new restorative and neuroprotective treatments in Parkinson's diseas. Nature, 1999, 399, A32-A39.
4. Riess, O.; Kruger, R. Parkinson's disease--a multifactorial neurodegenerative disorder. J. Neural Transm. Suppl., 1999, 56, 113-125.
5. Meredith, G.E.; Sonsalla, P.K.; Chesselet, M.F. Animal models of Parkinson's disease progression. Acta Neuropathol., 2008, 115, 385-398.
6. Bezard, E.; Gross, C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol., 1998, 55, 93-116.
7. Giraudo, M.D.; Gayraud, D.; Habib, M. Visuospatial ability of parkinsonians and elderly adults in location memory tasks. Brain Cogn., 1997, 34, 259-273.
8. Cools, R.; Barker, R.A.; Sahakian, B.J.; Robbins, T.W. Mechanisms of cognitive set flexibility in Parkinson's disease. Brain, 2001, 124, 2503-2512.
9. Lewis, S.J.; Dove, A.; Robbins, T.W.; Barker, R.A.; Owen, A.M. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J. Neurosci., 2003, 23, 6351-6356.
10. De Leonibus, E.; Manago, F.; Giordani, F.; Petrosino, F.; Lopez, S.; Oliverio, A.; Amalric, M.; Mele, A. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology, 2009, 34, 729-738.
11. McNamara, P.; Durso, R.; Brown, A.; Lynch, A. Counterfactual cognitive deficit in persons with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2003, 74, 1065-1070.
12. Morrison, C.E.; Borod, J.C.; Brin, M.F.; Halbig, T.D.; Olanow, C.W. Effects of levodopa on cognitive functioning in moderate-tosevere Parkinson's disease (MSPD). J. Neural Transm., 2004, 111, 1333-1341.
13. Ehringer, H.; Hornykiewicz, O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr., 1960, 38, 1236-1239.
14. Carlsson, A.; Lindqvist, M.; Magnusson, T. 3,4- Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 1957, 180, 1200.
15. Birkmayer, W.; Hornykiewicz, O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin. Wochenschr., 1961, 73, 787-788.
16. Cotzias, G.C.; Van Woert, M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 1961, 276, 374-379.
17. Hornykiewicz, O. A brief history of levodopa. J. Neurol., 2010, 257, S249-S252.
18. Lewitt, P.A. Levodopa for the treatment of Parkinson's disease. N. Engl. J. Med., 2008, 359, 2468-2476.
19. Olanow, C.W.; Obeso, J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology, 2000, 55, S72-S77.
20. Ahlskog, J.E.; Muenter, M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov. Disord., 2001, 16, 448-458.
21. Marsden, C.D.; Parkes, J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet, 1977, 345-349.
22. Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Lang, A.; Olanow, C.W.; Tanner, C.; Marek, K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 2004, 351, 2498-2508.
23. Nutt, J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology, 1990, 40, 340-345.
24. Obeso, J.A.; Olanow, C.W.; Nutt, J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci., 2000, 23, S2-S7.
25. Calne, D.B.; Plotkin, C.; Williams, A.C.; Nutt, J.G.; Neophytides, A.; Teychenne, P.F. Long-term treatment of parkinsonism with bromocriptine, Lancet, 1978, 1, 735-738.
26. Olanow, C.W.; Alberts, M.J. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease. Clin. Neuropharmacol., 1987, 10, 178-185.
27. Stocchi, F.; Tagliati, M.; Olanow, C.W. Treatment of levodopainduced motor complications. Mov. Disord., 2008, 23(Suppl 3), S599-S612.
28. Juncos, J.L.; Engber, T.M.; Raisman, R.; Susel, Z.; Thibaut, F.; Ploska, A.; Agid, Y.; Chase, T.N. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann. Neurol., 1989, 25, 473-478.
29. Olanow, C.W.; Obeso, J.A.; Stocchi, F. Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol., 2006, 5, 677-687.
30. Stocchi, F.; Vacca, L.; Ruggieri, S.; Olanow, C.W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol., 2005, 62, 905-910.
31. Knoll, J. The pharmacology of (-)deprenyl. J. Neural Transm., 1985, Suppl 22, 75-89.
32. Guldberg, H.C.; Marsden, C.A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol. Rev., 1975, 27, 135-206.
33. Mannisto, P.T.; Ulmanen, I.; Lundstrom, K.; Taskinen, J.; Tenhunen, J.; Tilgmann, C.; Kaakkola, S. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors Prog. Drug Res., 1992, 39, 291-350.
34. Salminen, M.; Lundstrom, K.; Tilgmann, C.; Savolainen, R.; Kalkkinen, N.; Ulmanen, I. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene, 1990, 93, 241-247.
35. Lundstrom, K.; Salminen, M.; Jalanko, A.; Savolainen, R.; Ulmanen, I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol., 1991, 10, 181-189.
36. Tenhunen, J.; Salminen, M.; Lundstrom, K.; Kiviluoto, T.; Savolainen, R.; Ulmanen, I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem., 1994, 223, 1049-1059.
37. Karhunen, T.; Tilgmann, C.; Ulmanen, I.; Julkunen, I.; Panula, P. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J. Histochem. Cytochem., 1994, 42, 1079-1090.
38. Karhunen, T.; Tilgmann, C.; Ulmanen, I.; Panula, P. Neuronal and non-neuronal catechol-O-methyltransferase in primary cultures of rat brain cells. Int. J. Dev. Neurosci., 1995, 13, 825-834.
39. Karhunen, T.; Tilgmann, C.; Ulmanen, I.; Panula, P. Catechol-Omethyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci. Lett., 1995, 187, 57-60.
40. Budygin, E.A.; Gainetdinov, R.R.; Kilpatrick, M.R.; Rayevsky, K.S.; Mannisto, P.T.; Wightman, R.M. Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur. J. Pharmacol., 1999, 370, 125-131.
41. Huotari, M.; Gainetdinov, R.; Mannisto, P.T. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol. Toxicol., 1999, 85, 233-238.
42. Tunbridge, E.M.; Bannerman, D.M.; Sharp, T.; Harrison, P.J. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J. Neurosci., 2004, 24, 5331-5335.
43. Gogos, J.A.; Morgan, M.; Luine, V.; Santha, M.; Ogawa, S.; Pfaff, D.; Karayiorgou, M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. USA, 1998, 95, 9991-9996.
44. Yavich, L.; Forsberg, M.M.; Karayiorgou, M.; Gogos, J.A.; Mannisto, P.T. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J. Neurosci., 2007, 27, 10196-10209.
45. Kaenmaki, M.; Tammimaki, A.; Myohanen, T.; Pakarinen, K.; Amberg, C.; Karayiorgou, M.; Gogos, J.A.; Mannisto, P.T. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J. Neurochem., 2010, 114, 1745-1755.
46. Miyamoto, J.K.; Uezu, E.; Terashima, S. Active transport pumps of HVA and DOPAC in dopaminergic nerve terminals. Physiol. Behav., 1991, 49, 141-147.
47. Mori, S.; Takanaga, H.; Ohtsuki, S.; Deguchi, T.; Kang, Y.S.; Hosoya, K.; Terasaki, T. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J. Cereb. Blood Flow Metab., 2003, 23, 432-440.
48. Nakazato, T.; Akiyama, A. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. Brain Res., 2002, 930, 134-142.
49. Nakazato, T. The medial prefrontal cortex mediates 3- methoxytyramine-induced behavioural changes in rat. Eur. J. Pharmacol., 2002, 442, 73-79.
50. Jonas, W.; Scheel-Kruger, J. Amphetamine induced stereotyped behaviour correlated with the accumulation of O-methylated dopamine. Arch. Int. Pharmacodyn. Ther., 1969, 177, 379-389.
51. Charlton, C.G.; Crowell, B., Jr. Effects of dopamine metabolites on locomotor activities and on the binding of dopamine: relevance to the side effects of L-dopa, Life Sci., 2000, 66, 2159-2171.
52. Sotnikova, T.D.; Beaulieu, J.M.; Espinoza, S.; Masri, B.; Zhang, X.; Salahpour, A.; Barak, L.S.; Caron, M.G.; Gainetdinov, R.R. The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS One, 2010, 5, e13452.
53. Barak, L.S.; Salahpour, A.; Zhang, X.; Masri, B.; Sotnikova, T.D.; Ramsey, A.J.; Violin, J.D.; Lefkowitz, R.J.; Caron, M.G.; Gainetdinov, R.R. Pharmacological characterization of membraneexpressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol. Pharmacol., 2008, 74, 585-594.
54. Bunzow, J.R.; Sonders, M.S.; Arttamangkul, S.; Harrison, L.M.; Zhang, G.; Quigley, D.I.; Darland, T.; Suchland, K.L.; Pasumamula, S.; Kennedy, J.L.; Olson, S.B.; Magenis, R.E.; Amara, S.G.; Grandy, D.K. Amphetamine, 3,4- methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol., 2001, 60, 1181-1188.
55. Muskiet, F.A.; Groen, A. Urinary excretion of conjugated homovanillic acid, 3,4-dihydroxyphenylacetic acid, phydroxyphenylacetic acid, and vanillic acid by persons on their usual diet and patients with neuroblastoma. Clin. Chem., 1979, 25, 1281-1284.
56. Siirtola, T.; Sonninen, V.; Rinne, U.K. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. Clin. Neurol. Neurosurg., 1975, 78, 77-88.
57. Rajput, A.H.; Fenton, M.E.; Di Paolo, T.; Sitte, H.; Pifl, C.; Hornykiewicz, O. Human brain dopamine metabolism in levodopainduced dyskinesia and wearing-off. Parkinsonism Relat. Disord., 2004, 10, 221-226.
58. Sotnikova, T.D.; Zorina, O.I.; Ghisi, V.; Caron, M.G.; Gainetdinov, R.R. Trace amine associated receptor 1 and movement control. Parkinsonism Relat. Disord., 2008, 14(Suppl 2), S99-S102.
59. Sotnikova, T.D.; Caron, M.G.; Gainetdinov, R.R. Trace amineassociated receptors as emerging therapeutic targets. Mol. Pharmacol., 2009, 76, 229-235.
60. Espinoza, S.; Salahpour, A.; Masri, B.; Sotnikova, T.D.; Messa, M.; Barak, L.S.; Caron, M.G.; Gainetdinov, R.R. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol. Pharmacol., 2011, 80, 416-425.
61. Grandy, D.K. Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol. Ther., 2007, 116, 355-390.
62. Revel, F.G.; Moreau, J.L.; Gainetdinov, R.R.; Bradaia, A.; Sotnikova, T.D.; Mory, R.; Durkin, S.; Zbinden, K.G.; Norcross, R.; Meyer, C.A.; Metzler, V.; Chaboz, S.; Ozmen, L.; Trube, G.; Pouzet, B.; Bettler, B.; Caron, M.G.; Wettstein, J.G.; Hoener, M.C. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl. Acad. Sci. USA, 2011, 108, 8485-8490.
63. Ericsson, A.D. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J. Neurol. Sci., 1971, 14, 193-197.
64. Reches, A.; Fahn, S. Catechol-O-methyltransferase and Parkinson's disease. Adv. Neurol., 1984, 40, 171-179.
65. Baldessarini, R.J.; Chace, K.V. Metabolism of L-dopa after inhibition of catechol-O-methyl transferase. Eur. J. Pharmacol., 1972, 17, 163-166.
66. Backstrom, R.; Honkanen, E.; Pippuri, A.; Kairisalo, P.; Pystynen, J.; Heinola, K.; Nissinen, E.; Linden, I.B.; Mannisto, P.T.; Kaakkola, S.; Pohto, P. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J. Med. Chem., 1989, 32, 841-846.
67. Borgulya, J.; Bruderer, H.; Bernauer, K.; Zürcher, G.; Prada, M.D. Catechol-O-methyltransferase-Inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv. Chim. Acta, 1989, 72, 952-968.
68. Bonifacio, M.J.; Palma, P.N.; Almeida, L.; Soares-da-Silva, P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev., 2007, 13, 352-379.
69. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melen, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry, 1995, 34, 4202-4210.
70. Schultz, E.; Nissinen, E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem. Pharmacol., 1989, 38, 3953-3956.
71. Nissinen, E.; Mannisto, P.T. Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. Int. Rev. Neurobiol., 2010, 95, 73-118.
72. Nissinen, E.; Linden, I.B.; Schultz, E.; Kaakkola, S.; Mannisto, P.T.; Pohto, P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol., 1988, 153, 263-269.
73. Mannisto, P.T.; Kaakkola, S.; Nissinen, E.; Linden, I.B.; Pohto, P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase, Life Sci., 1988, 43, 1465-1471.
74. Ferreira, J.J.; Almeida, L.; Cunha, L.; Ticmeanu, M.; Rosa, M.M.; Januario, C.; Mitu, C.E.; Coelho, M.; Correia-Guedes, L.; Morgadinho, A.; Nunes, T.; Wright, L.C.; Falcao, A.; Sampaio, C.; Soares-da-Silva, P. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin. Neuropharmacol., 2008, 31, 2-18.
75. Ferreira, J.J.; Rascol, O.; Poewe, W.; Sampaio, C.; Rocha, J.F.; Nunes, T.; Almeida, L.; Soares-da-Silva, P. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci. Ther., 2010, 16, 337-347.
76. Nissinen, E.; Linden, I.B.; Schultz, E.; Pohto, P. Biochemical and pharmacological properties of a peripherally acting catechol-Omethyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch. Pharmacol., 1992, 346, 262-266.
77. Zurcher, G.; Keller, H.H.; Kettler, R.; Borgulya, J.; Bonetti, E.P.; Eigenmann, R.; Da Prada, M. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv. Neurol., 1990, 53, 497-503.
78. Zurcher, G.; Colzi, A.; Da Prada, M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J. Neural Transm. Suppl., 1990, 32, 375-380.
79. Mannisto, P.T.; Tuomainen, P.; Tuominen, R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol., 1992, 105, 569-574.
80. Tornwall, M.; Kaakkola, S.; Tuomainen, P.; Kask, A.; Mannisto, P.T. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats. Br. J. Pharmacol., 1994, 112, 13-18.
81. Kaakkola, S.; Wurtman, R.J. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res., 1992, 587, 241-249.
82. Linden, I.B.; Nissinen, E.; Etemadzadeh, E.; Kaakkola, S.; Mannisto, P.; Pohto, P. Favorable effect of catechol-Omethyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther., 1988, 247, 289-293.
83. Napolitano, A.; Bellini, G.; Borroni, E.; Zurcher, G.; Bonuccelli, U. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats, Parkinsonism Relat. Disord., 2003, 9, 145-150.
84. Learmonth, D.A.; Vieira-Coelho, M.A.; Benes, J.; Alves, P.C.; Borges, N.; Freitas, A.P.; da-Silva, P.S. Synthesis of 1-(3,4- dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-Omethyltransferase. J. Med. Chem., 2002, 45, 685-695.
85. Learmonth, D.A.; Palma, P.N.; Vieira-Coelho, M.A.; Soares-da-Silva, P. Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-Omethyltransferase. J. Med. Chem., 2004, 47, 6207-6217.
86. Bonifacio, M.J.; Archer, M.; Rodrigues, M.L.; Matias, P.M.; Learmonth, D.A.; Carrondo, M.A.; Soares-Da-Silva, P. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol. Pharmacol., 2002, 62, 795-805.
87. Palma, P.N.; Rodrigues, M.L.; Archer, M.; Bonifacio, M.J.; Loureiro, A.I.; Learmonth, D.A.; Carrondo, M.A.; Soares-da-Silva, P. Comparative study of orthoand meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation. Mol. Pharmacol., 2006, 70, 143-153.
88. Kiss, L.E.; Ferreira, H.S.; Torrao, L.; Bonifacio, M.J.; Palma, P.N.; Soares-da-Silva, P.; Learmonth, D.A. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem., 2010, 53, 3396-3411.
89. Waldmeier, P.C.; De Herdt, P.; Maitre, L. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and Omethylation of exogenous L-dopa in the rat. J. Neural Transm. Suppl., 1990, 32, 381-386.
90. Waldmeier, P.C.; Baumann, P.A.; Feldtrauer, J.J.; Hauser, K.; Bittiger, H.; Bischoff, S.; von Sprecher, G. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch. Pharmacol., 1990, 342, 305-311.
91. Tornwall, M.; Mannisto, P.T. Effects of three types of catechol Omethylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur. J. Pharmacol., 1993, 250, 77-84.
92. Anderson, G.L.; Bussolotti, D.L.; Coward, J.K. Synthesis and evaluation of some stable multisubstrate adducts as inhibitors of catechol O-methyltransferase. J. Med. Chem., 1981, 24, 1271-1277.
93. Lerner, C.; Ruf, A.; Gramlich, V.; Masjost, B.; Zurcher, G.; Jakob-Roetne, R.; Borroni, E.; Diederich, F. X-ray Crystal Structure of a Bisubstrate Inhibitor Bound to the Enzyme Catechol-Omethyltransferase: A Dramatic Effect of Inhibitor Preorganization on Binding Affinity. Angew Chem. Int. Ed. Engl., 2001, 40, 4040-4042.
94. Masjost, B.; Ballmer, P.; Borroni, E.; Zurcher, G.; Winkler, F.K.; Jakob-Roetne, R.; Diederich, F. Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol Omethyltransferase (COMT) Chemistry, 2000, 6, 971-982.
95. Lees, A.J. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci. Ther., 2008, 14, 83-93.
96. Ungerstedt, U.; Arbuthnott, G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res., 1970, 24, 485-493.
97. Jenner, P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15(Suppl 4), S18-S23.
98. Maj, J.; Rogoz, Z.; Skuza, G.; Sowinska, H.; Superata, J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect., 1990, 2, 101-112.
99. Fredriksson, A.; Archer, T. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. J. Neural Transm. Gen. Sect., 1995, 102, 19-34.
100. Etemadzadeh, E.; Koskinen, L.; Kaakkola, S. Computerized rotometer apparatus for recording circling behavior. Methods Find. Exp. Clin. Pharmacol., 1989, 11, 399-407.
101. Smith, L.A.; Gordin, A.; Jenner, P.; Marsden, C.D. Entacapone enhances levodopa-induced reversal of motor disability in MPTPtreated common marmosets. Mov. Disord., 1997, 12, 935-945.
102. Marin, C.; Aguilar, E.; Bonastre, M.; Tolosa, E.; Obeso, J.A. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp. Neurol., 2005, 192, 184-193.
103. Marin, C.; Aguilar, E.; Mengod, G.; Cortes, R.; Obeso, J.A. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. Eur. J. Neurosci., 2007, 25, 259-269.
104. Muenter, M.D.; Tyce, G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin. Proc., 1971, 46, 231-239.
105. Nutt, J.G.; Carter, J.H.; Woodward, W.R. Long-duration response to levodopa. Neurology, 1995, 45, 1613-1616.
106. Zappia, M.; Colao, R.; Montesanti, R.; Rizzo, M.; Aguglia, U.; Gambardella, A.; Oliveri, R.L.; Quattrone, A. Long-duration response to levodopa influences the pharmacodynamics of shortduration response in Parkinson's disease. Ann. Neurol., 1997, 42, 245-248.
107. Marin, C.; Aguilar, E.; Mengod, G.; Cortes, R.; Rodriguez-Oroz, M.C.; Obeso, J.A. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. Neurobiol. Dis., 2008, 32, 340-348.
108. Del Sorbo, F.; Albanese, A. Levodopa-induced dyskinesias and their management. J. Neurol., 2008, 255(Suppl 4), 32-41.
109. Schneider, J.S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav., 1989, 34, 193-196.
110. Cenci, M.A.; Ohlin, K.E. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15(Suppl 4), S13-S17.
111. Marin, C.; Aguilar, E.; Obeso, J.A. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov. Disord., 2006, 21, 646-653.
112. Smith, L.A.; Jackson, M.J.; Al-Barghouthy, G.; Rose, S.; Kuoppamaki, M.; Olanow, W.; Jenner, P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drugnaive primates. Mov. Disord., 2005, 20, 306-314.
113. Poulopoulos, M.; Waters, C. Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evid., 2010, 5, 1-10.
114. Stocchi, F.; Rascol, O.; Kieburtz, K.; Poewe, W.; Jankovic, J.; Tolosa, E.; Barone, P.; Lang, A.E.; Olanow, C.W. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol., 2010, 68, 18-27.
115. Jorga, K.M. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology, 1998, 50, S31-S38.
116. Heikkinen, H.; Saraheimo, M.; Antila, S.; Ottoila, P.; Pentikainen, P.J. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur. J. Clin. Pharmacol., 2001, 56, 821-826.
117. Mannisto, P.T.; Kaakkola, S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev., 1999, 51, 593-628.
118. Keranen, T.; Gordin, A.; Karlsson, M.; Korpela, K.; Pentikainen, P.J.; Rita, H.; Schultz, E.; Seppala, L.; Wikberg, T. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol., 1994, 46, 151-157.
119. Dingemanse, J.; Jorga, K.M.; Schmitt, M.; Gieschke, R.; Fotteler, B.; Zurcher, G.; Da Prada, M.; van Brummelen, P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-Omethyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther., 1995, 57, 508-517.
120. Almeida, L.; Soares-da-Silva, P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs RD, 2003, 4, 207-217.
121. Wikberg, T.; Vuorela, A.; Ottoila, P.; Taskinen, J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos., 1993, 21, 81-92.
122. Dingemanse, J.; Jorga, K.; Zurcher, G.; Fotteler, B.; Sedek, G.; Nielsen, T.; van Brummelen, P. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol., 1996, 50, 47-55.
123. Sedek, G.; Jorga, K.; Schmitt, M.; Burns, R.S.; Leese, P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol., 1997, 20, 531-541.
124. Jorga, K.; Fotteler, B.; Sedek, G.; Nielsen, T.; Aitken, J. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J. Neurol., 1998, 245, 223-230.
125. Keranen, T.; Gordin, A.; Harjola, V.P.; Karlsson, M.; Korpela, K.; Pentikainen, P.J.; Rita, H.; Seppala, L.; Wikberg, T. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol., 1993, 16, 145-156.
126. Jorga, K.M.; Sedek, G.; Fotteler, B.; Zurcher, G.; Nielsen, T.; Aitken, J.W. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther., 1997, 62, 300-310.
127. Ahtila, S.; Kaakkola, S.; Gordin, A.; Korpela, K.; Heinavaara, S.; Karlsson, M.; Wikberg, T.; Tuomainen, P.; Mannisto, P.T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol., 1995, 18, 46-57.
128. Nyholm, D.; Askmark, H.; Aquilonius, S.M. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. Ann. Neurol., 2011, 69, 424; author reply 425.
129. Solla, P.; Cannas, A.; Marrosu, F.; Marrosu, M.G. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr. Dis. Treat., 2010, 6, 483-490.
130. Truong, D.D. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin. Interv. Aging, 2009, 4, 109-113.
131. Olanow, C.W. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch. Neurol., 2000, 57, 263-267.
132. Rinne, U.K.; Larsen, J.P.; Siden, A.; Worm-Petersen, J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology, 1998, 51, 1309-1314.
133. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol., 1997, 42, 747-755.
134. Fenelon, G.; Gimenez-Roldan, S.; Montastruc, J.L.; Bermejo, F.; Durif, F.; Bourdeix, I.; Pere, J.J.; Galiano, L.; Schadrack, J. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J. Neural Transm., 2003, 110, 239-251.
135. Larsen, J.P.; Worm-Petersen, J.; Siden, A.; Gordin, A.; Reinikainen, K.; Leinonen, M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur. J. Neurol., 2003, 10, 137-146.
136. Onofrj, M.; Thomas, A.; Vingerhoets, F.; Martin, W.; Gimenez-Roldan, S.; Azulay, J.P.; Bernhard, G.; Schmidt, W.; Markabi, S. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J. Neural Transm., 2004, 111, 1053-1063.
137. Poewe, W.H.; Deuschl, G.; Gordin, A.; Kultalahti, E.R.; Leinonen, M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand., 2002, 105, 245-255.
138. Olanow, C.W.; Kieburtz, K.; Stern, M.; Watts, R.; Langston, J.W.; Guarnieri, M.; Hubble, J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch. Neurol., 2004, 61, 1563-1568.
139. Hauser, R.A. Levodopa/carbidopa/entacapone (Stalevo). Neurology, 2004, 62, S64-S71.
140. Brooks, D.J.; Agid, Y.; Eggert, K.; Widner, H.; Ostergaard, K.; Holopainen, A. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur. Neurol., 2005, 53, 197-202.
141. Eggert, K.; Skogar, O.; Amar, K.; Luotonen, L.; Kuoppamaki, M.; Leinonen, M.; Nissinen, H.; Oertel, W. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. J. Neural Transm., 2010, 117, 333-342.
142. Adler, C.H.; Singer, C.; O'Brien, C.; Hauser, R.A.; Lew, M.F.; Marek, K.L.; Dorflinger, E.; Pedder, S.; Deptula, D.; Yoo, K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol., 1998, 55, 1089-1095.
143. Myllyla, V.V.; Kultalahti, E.R.; Haapaniemi, H.; Leinonen, M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur. J. Neurol., 2001, 8, 53-60.
144. Baas, H.; Beiske, A.G.; Ghika, J.; Jackson, M.; Oertel, W.H.; Poewe, W.; Ransmayr, G. Catechol-O-methyltransferase inhibition with tolcapone reduces the wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry, 1997, 63, 421-428.
145. Rajput, A.H.; Martin, W.; Saint-Hilaire, M.H.; Dorflinger, E.; Pedder, S. Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology, 1997, 49, 1066-1071.
146. Factor, S.A.; Molho, E.S.; Feustel, P.J.; Brown, D.L.; Evans, S.M. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol., 2001, 24, 295-299.
147. Onofrj, M.; Thomas, A.; Iacono, D.; Di Iorio, A.; Bonanni, L. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol., 2001, 46, 11-16.
148. Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: Multicenter double-blind, randomized, activecontrolled trial in advanced Parkinson's disease. Mov. Disord., 2007, 22, 14-19.
149. Haasio, K. Toxicology and safety of COMT inhibitors. Int. Rev. Neurobiol., 2010, 95, 163-189.
150. Lees, A.J.; Ratziu, V.; Tolosa, E.; Oertel, W.H. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2007, 78, 944-948.
151. Haasio, K.; Nissinen, E.; Sopanen, L.; Heinonen, E.H. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J. Neural Transm., 2002, 109, 1391-1401.
152. Nissinen, E.; Kaheinen, P.; Penttila, K.E.; Kaivola, J.; Linden, I.B. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur. J. Pharmacol., 1997, 340, 287-294.
153. Kunugi, H.; Nanko, S.; Ueki, A.; Otsuka, E.; Hattori, M.; Hoda, F.; Vallada, H.P.; Arranz, M.J.; Collier, D.A. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci. Lett., 1997, 221, 202-204.
154. Wu, R.M.; Cheng, C.W.; Chen, K.H.; Lu, S.L.; Shan, D.E.; Ho, Y.F.; Chern, H.D. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology, 2001, 56, 375-382.
155. Chen, J.; Lipska, B.K.; Halim, N.; Ma, Q.D.; Matsumoto, M.; Melhem, S.; Kolachana, B.S.; Hyde, T.M.; Herman, M.M.; Apud, J.; Egan, M.F.; Kleinman, J.E.; Weinberger, D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet., 2004, 75, 807-821.
156. Eerola, J.; Launes, J.; Hellstrom, O.; Tienari, P.J. Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland. Neurosci. Lett., 2002, 330, 296-298.
157. Contin, M.; Martinelli, P.; Mochi, M.; Riva, R.; Albani, F.; Baruzzi, A. Genetic polymorphism of catechol-Omethyltransferase and levodopa pharmacokineticpharmacodynamic pattern in patients with Parkinson's disease. Mov. Disord., 2005, 20, 734-739.
158. McLeod, H.L.; Syvanen, A.C.; Githang'a, J.; Indalo, A.; Ismail, D.; Dewar, K.; Ulmanen, I.; Sludden, J. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics, 1998, 8, 195-199.
159. Corvol, J.C.; Bonnet, C.; Charbonnier-Beaupel, F.; Bonnet, A.M.; Fievet, M.H.; Bellanger, A.; Roze, E.; Meliksetyan, G.; Ben Djebara, M.; Hartmann, A.; Lacomblez, L.; Vrignaud, C.; Zahr, N.; Agid, Y.; Costentin, J.; Hulot, J.S.; Vidailhet, M. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann. Neurol., 2011, 69, 111-118.
160. Nackley, A.G.; Shabalina, S.A.; Tchivileva, I.E.; Satterfield, K.; Korchynskyi, O.; Makarov, S.S.; Maixner, W.; Diatchenko, L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science, 2006, 314, 1930-1933.
161. Bialecka, M.; Drozdzik, M.; Klodowska-Duda, G.; Honczarenko, K.; Gawronska-Szklarz, B.; Opala, G.; Stankiewicz, J. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol. Scand., 2004, 110, 260-266.
162. Foltynie, T.; Goldberg, T.E.; Lewis, S.G.; Blackwell, A.D.; Kolachana, B.S.; Weinberger, D.R.; Robbins, T.W.; Barker, R.A. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov. Disord., 2004, 19, 885-891.
163. Woitalla, D.; Karwasz, R.; Muller, T.; Przuntek, H.; Kuhn, W. The activity of catechol-O-methyltransferase in parkinsonian patients with on-off fluctuations. J. Neural Transm., 2000, 107, 105-111.
164. Williams-Gray, C.H.; Hampshire, A.; Robbins, T.W.; Owen, A.M.; Barker, R.A. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J. Neurosci., 2007, 27, 4832-4838.
165. Williams-Gray, C.H.; Hampshire, A.; Barker, R.A.; Owen, A.M. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain, 2008, 131, 397-408.
166. Watanabe, M.; Harada, S.; Nakamura, T.; Ohkoshi, N.; Yoshikawa, K.; Hayashi, A.; Shoji, S. Association between catechol-Omethyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology, 2003, 48, 190-193.
167. Lee, M.S.; Lyoo, C.H.; Ulmanen, I.; Syvanen, A.C.; Rinne, J.O. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci. Lett., 2001, 298, 131-134.
168. Reilly, D.K.; Hershey, L.; Rivera-Calimlim, L.; Shoulson, I. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Adv. Neurol., 1983, 37, 51-60.
169. Gordin, A.; Kaakkola, S.; Teravainen, H. Clinical advantages of COMT inhibition with entacapone - a review. J. Neural Transm., 2004, 111, 1343-1363.